<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495077</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT CTOT-19</org_study_id>
    <nct_id>NCT02495077</nct_id>
  </id_info>
  <brief_title>Effects of Inhibiting Early Inflammation in Kidney Transplant Patients</brief_title>
  <official_title>Randomized Controlled Trial of Infliximab (RemicadeÂ®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trials in Organ Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During transplant surgery, there is a period of time when a donated kidney is removed from a
      donor's body and stored until the time of the transplant surgery. The storage procedure
      results in buildup of various proteins within the kidney that can injure the donated kidney
      after it is transplanted. One of these proteins is tumor necrosis factor-alpha (TNF-alpha).

      The purpose of this study is to evaluate whether taking infliximab, which blocks TNF-alpha,
      just prior to transplant surgery along with usual transplant medicines will protect the
      donated kidney from damage caused by TNF-alpha and help keep the transplanted kidney healthy
      for a longer period of time.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between the mean eGFR (modified MDRD) in the experimental vs. control groups.</measure>
    <time_frame>24-Month post-transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute cellular rejection (BPAR)</measure>
    <time_frame>6 month post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute cellular rejection (BPAR).</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BANFF grades of first Acute Cellular Rejections (ACR).</measure>
    <time_frame>6 month post-transplantation</time_frame>
    <description>Based on BANFF 2007 Scoring Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute cellular rejection (BPAR) or borderline rejection.</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute cellular rejection (BPAR) or borderline rejection</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute antibody mediated rejection (AMR)</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute antibody mediated rejection (AMR).</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute antibody mediated rejection AMR or suspicious for AMR</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute antibody mediated rejection AMR or suspicious for AMR.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BANFF grades of first AMR.</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BANFF chronicity scores &gt; or equal 2.</measure>
    <time_frame>24 month post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BANFF chronicity scores Change Between implantation and 24 month biopsies.</measure>
    <time_frame>24 month post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR between 3 months and 24 months</measure>
    <time_frame>24 month post-transplantation</time_frame>
    <description>As measured by both MDRD and Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR between post-transplant nadir and 24 months</measure>
    <time_frame>24 month post-transplantation</time_frame>
    <description>As measured by both MDRD and CKD-EPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR Values</measure>
    <time_frame>On days 7, 30, 90, and 180 post-transplantation</time_frame>
    <description>As measured by both MDRD and CKD-EPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with death or graft failure.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with only graft failure.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that required at least one dialysis treatment.</measure>
    <time_frame>1 week post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dialysis sessions.</measure>
    <time_frame>8 weeks post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of delayed graft function (DGF) defined from transplantation to the last required dialysis treatment.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of primary non-function (PNF), defined as for dialysis-dependency for more than 3 months.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (immediately after surgery) in serum creatinine and serum creatinine concentration.</measure>
    <time_frame>24, 48 and 72 hours post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event (ACR, AMR, or hospitalization for infection and or malignancy)</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Slow Graft Function (SGF)</measure>
    <time_frame>Day 5 post-transplantation</time_frame>
    <description>The proportion of patients with a serum creatinine of more than 3 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Slow Graft Function (SGF)</measure>
    <time_frame>Day 2 and 7 post-transplantation</time_frame>
    <description>Creatinine reduction ratio (CRR) defined as the first creatinine on the day divided by the first creatinine after surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Slow Graft Function (SGF)</measure>
    <time_frame>Day 5 post-transplantation</time_frame>
    <description>The proportion of patients whose day 5 serum CRR was less than 70%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Slow Graft Function (SGF)</measure>
    <time_frame>Day 2 post-transplantation</time_frame>
    <description>The proportion of patients whose day 2 serum CRR was less than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Slow Graft Function</measure>
    <time_frame>1 week post-transplantation</time_frame>
    <description>Proportion of subjects who need dialysis after 1 week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with any infection requiring hospitalization or resulting in death.</measure>
    <time_frame>5 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Mycobacterial or fungal infections</measure>
    <time_frame>5 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with CMV viremia require a change in immunosuppression or anti-viral treatment as per standard of care at the site</measure>
    <time_frame>5 years post-transplantation</time_frame>
    <description>as per standard of care at the site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BK viremia that require a change in immunosuppression or anti-viral treatment as per standard of care at the site.</measure>
    <time_frame>5 years</time_frame>
    <description>as per standard of care at the site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with malignancy.</measure>
    <time_frame>5 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with impaired wound healing manifested by wound dehiscence, wound infection, or hernia at the site of the transplant incision</measure>
    <time_frame>5 years post-transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rATG is co-administered with anti-TNFa (infliximab/Remicade) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rabbit anti-thymocyte globulin (rATG, Thymoglobulin) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>A single dose, of 3mg/kg infusion</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Administered at a target dose of 2000mg daily, as tolerated, until study closure</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>FR-900506</other_name>
    <other_name>Prograf</other_name>
    <other_name>Prograft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Anti-Thymocyte Globulin [Rabbit]</other_name>
    <other_name>Rabbit ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>30 to 60 minutes prior to the start of the infusion
Tylenol, 600 to 1000mg by mouth or
Suppository form</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>30 to 60 minutes prior to the start of the infusion
Claritin (Loratadine) 10mg by mouth or
Benadryl (Diphenhydramine) 25 or 50 mg by mouth</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Claritin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for Infliximab</intervention_name>
    <description>A single dose is volume matched to Infliximab (250mL) infusion</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>30 to 60 minutes prior to the start of the infusion
Claritin (Loratadine) 10mg by mouth or
Benadryl (Diphenhydramine) 25 or 50 mg by mouth</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (&gt;18 years of age) male and female recipients (all races and ethnicities)

          2. Subject must be able to understand and provide consent

          3. Recipients of deceased donor kidney transplants (including re-transplants)

          4. Negative crossmatch, actual or virtual, or a PRA of 0% on historic and current sera as
             determined by each participating study center.

          5. Donor kidneys from deceased donors and donors after cardiac death (DCD) with Kidney
             Donor Profile Indices (KDPI) ranging from &gt;35 to &lt;95

          6. Female participants of childbearing potential must have a negative pregnancy test upon
             study entry

        Exclusion Criteria:

          1. Inability or unwillingness of a participant to give written informed consent or comply
             with study protocol

          2. Recipients of living donor transplants

          3. Presence of other transplanted solid organ (heart, lung, liver, pancreas, small
             intestines) or co-transplanted organ

          4. HIV+ recipients

          5. EBV negative recipients

          6. Hepatitis B surface antigen positive kidney transplant recipients

          7. Hepatitis B core antibody positive kidney transplant recipients

          8. Hepatitis B negative kidney transplant recipients that receive transplants from
             Hepatitis B core antibody positive donor

          9. Hepatitis C Virus positive (HCV+) patients who are either untreated or have failed to
             demonstrate sustained viral remission for more than 12 months after anti-viral
             treatment

         10. Recipients with a previous history of active TB

         11. Patients with a positive test for TB exposure (PPD, QuantiFERON, ELISPOT) without
             history of active infection who have NOT completed a full course of INH
             therapy.Subjects must have TB test within 1 year prior to transplant. (Refer to
             Section 8 for additional information)

         12. Any infection at the time of transplantation

         13. Severe congestive heart failure (NYHA functional class III or higher)

         14. Subjects with a known hypersensitivity to any murine/ mouse proteins.

         15. Subjects with any history of receiving any anti-TNF products

         16. Subjects in whom rATG or infliximab might not be tolerated

         17. Subjects with less than 3000/mm^3 WBC

         18. Subjects with less than 100,000/mm^3 platelets counts

         19. Subjects with systolic blood pressure &lt; 100 mm/Hg

         20. Subjects with symptomatic orthostatic hypotension or currently requiring Midodrine for
             blood pressure support.

         21. Subjects from or who have traveled to endemic areas with a history of active
             histoplasmosis or with a CXR consistent with previous active histoplasmosis (no
             serological testing required). Endemic regions determined by site based on local
             standard of care.

         22. Subjects currently or formerly residing in regions of the US that are highly endemic
             for coccidioidomycosis, and who have a positive serologic test for coccidioidomycosis.
             Endemic regions determined by site based on local standard of care.

         23. Recipients are excluded if the local site decides to treat the recipient with
             fluconazole because of diagnosis or suspicion of fungal infection the donor.

         24. Subjects that receive IVIG treatment within 3 months of transplant or planned IVIG
             treatment peritransplant.

         25. Use of an investigational agent within 4-weeks prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Heeger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald E Hricik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Harmon</last_name>
      <phone>205-996-9632</phone>
      <email>eharmon@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Roslyn B. Mannon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suphamai Bunnapradist</last_name>
      <phone>310-794-8516</phone>
      <email>bunnapradist@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Janette Gadzhyan, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Fernandez</last_name>
      <phone>415-353-8380</phone>
      <email>Emilio.Fernandez@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Flavio Vincenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricarda Tomlin</last_name>
      <phone>203-785-2073</phone>
      <email>ricarda.tomlin@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Formica Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Ferry</last_name>
      <phone>404-712-1816</phone>
      <email>elizabeth.ferry@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Newell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Ramirez</last_name>
      <phone>410-328-0303</phone>
      <email>rramirez@som.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Bartosic</last_name>
      <phone>(410) 328-0303</phone>
      <email>abartosic@som.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan S. Bromberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mullaney Marlene</last_name>
      <phone>410-614-6702</phone>
      <email>mmulla13@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Darin Ostrander</last_name>
      <phone>(410) 614-6702</phone>
      <email>dostran1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel C. Brennan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mawby</last_name>
      <phone>734-936-4811</phone>
      <email>jlmawby@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Randall Sung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cusanelli Rebecca</last_name>
      <phone>314-362-4109</phone>
      <email>rcusanel@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Tarek Alhamad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Wilson</last_name>
      <phone>212-659-8049</phone>
      <email>Douglas.Wilson@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Madhav Menon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Heeger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Sendrey</last_name>
      <phone>216-444-0486</phone>
      <email>sendred2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Emilio Poggio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Lee</last_name>
      <phone>216-844-5396</phone>
      <email>tracey.lee@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Donald Hricik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Stucke</last_name>
      <phone>608-265-1257</phone>
      <email>stucke@surgery.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>David Foley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Slivinski</last_name>
      <phone>(204) 787-8662</phone>
      <email>cslivinski@exchange.hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Peter Nickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Rush, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz Marie Gumabay</last_name>
      <phone>(416) 340-4800</phone>
      <phone_ext>6806</phone_ext>
      <email>franzmarie.gumabay@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Kathryn Tinckam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.ctotstudies.org/</url>
    <description>Clinical Trials in Organ Transplantation (CTOT)</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>infliximab</keyword>
  <keyword>Tissue Donors</keyword>
  <keyword>Remicade</keyword>
  <keyword>Induction Therapy</keyword>
  <keyword>Deceased Donor Kidney Transplant Recipients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

